Why collaboration is key to successfully scaling up at speed, in the context of developing, manufacturing and scaling up a vaccine for Covid-19.
PLAY VIDEO ABOVE * Oxford Biomedica, the sponsor of this content would like to send you information about their products and services. If you do not wish to receive these emails, click here to opt out.
When Covid-19 hit, scientists around the world worked together to address the huge challenge of producing an effective vaccine against the virus. It was this strong collaboration and expertise drawn from industry, academia, regulators and governments that made it possible to develop and manufacture a vaccine at speed. To date, more than 1.3 billion doses of the adenovirus-vectored vaccine ChAdOx1 nCoV-19 (AZD1222, Vaxzevria) have been released for use.
During the pandemic, manufacturing has been the key factor limiting rollout of vaccination, requiring rapid development and large-scale implementation of novel manufacturing technologies.
This webinar will discuss the unique challenges when scaling up GMP manufacturing, exacerbated by the need to move at a very high speed whilst always ensuring that safety and regulatory requirements were satisfied.
Discover how Oxford Biomedica collaborated with The Jenner Institute to develop and manufacture the vaccine by ensuring the necessary skills, capacity, process and supply chains were all in place to help manufacture at the utmost speed and scale to meet the global demand for vaccine supplies.
Join James Miskin, Chief Technical Officer at Oxford Biomedica, Sandy Douglas, Research Group Leader at the University of Oxford, and Jessica Carmen, Executive Vice President at Adjuvant Partners, as they discuss some of the key challenges associated with developing and commercialising an effective Covid-19 vaccine and the application of these ideas to the advanced therapies commercialisation journey.
Learn how to…
>> Efficiently develop a highly productive and cost-effective GMP manufacturing process
>> Ensure safety and regulatory requirements are satisfied, and learn what a productive regulatory relationship looks like
>> Overcome novel CMC challenges through innovative thinking and pooled expertise
>> Harness a potentially unique strategy of distributed manufacturing of a therapeutic across a global network of site
>> Establish collaborations between academia, contract manufacturers and large pharma, and how to navigate these partnership opportunities
>> Recruit, train and retain talent to ensure high-capacity demand is met with a highly skilled and engaged workforce
Do you have questions for our panellists? Submit them via the Q&A widget during the live event, or pose them via the event page on the network.
This webinar was hosted in partnership with Oxford Biomedica.